PhRMA Statement on Global Intellectual Property Agenda: 2009 Special 301 Report

Washington, D.C. (May 4, 2009) — Chris Singer, president of the International Section of the Pharmaceutical Research and Manufacturers of America, issued the following statement today on the U.S. Trade Representative’s (USTR) "Special 301" annual report to Congress, outlining the Administration’s global intellectual property agenda:

A Decade of Innovation

R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges

Washington, D.C. (March 10, 2009) — Despite the nation’s economic slowdown, America’s pharmaceutical research and biotechnology companies invested a record $65.2 billion last year in the research and development of new life-changing medicines and vaccines – an increase of roughly $2 billion from 2007, according to analyses by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Burrill & Company.

PhRMA Statement on Patent Reform Act of 2009

Washington, D.C. (March 3, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today:

“We appreciate the work done by the bill's sponsors to work with all stakeholders and bring forward legislation on this important topic. However, we remain concerned that the legislation introduced today does not address the concerns of numerous stakeholders from many industries who would be negatively affected by certain provisions in the bill.

PhRMA 301 Submission Supports Global Intellectual Property Priorities

Washington, D.C. (February 17, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement regarding PhRMA’s 2009 Special 301 submission (read the report), which outlines global intellectual property priorities:

Drug Discovery and Development

Decade of Innovation: Advances in the Treatment of Rare Diseases


Subscribe to RSS - Innovation